These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 34959188)
1. Future of antivirals in COVID-19: The case of favipiravir. Kow CS; Ramachandram DS; Hasan SS Int Immunopharmacol; 2022 Feb; 103():108455. PubMed ID: 34959188 [No Abstract] [Full Text] [Related]
2. Favipiravir for the Treatment of Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Naveed A; Cheema HA; Shahid A; Umer M; Hussain HU; Rehman MEU; Singh H; Kurman JS; Sahra S; Ahmad F; Ahmad S; Iqbal S Am J Ther; 2024 Jul-Aug 01; 31(4):e478-e482. PubMed ID: 38260985 [No Abstract] [Full Text] [Related]
3. Efficacy and Safety of Favipiravir for the Treatment of COVID-19 Outpatients: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Cheema HA; Ali A; Ali M; Shahid A; Ghafoor MS; Ur Rehman ME; Sah R; Sahra S; Ahmad S Am J Ther; 2024 May-Jun 01; 31(3):e328-e331. PubMed ID: 37647511 [No Abstract] [Full Text] [Related]
4. Favipiravir, an antiviral for COVID-19? Coomes EA; Haghbayan H J Antimicrob Chemother; 2020 Jul; 75(7):2013-2014. PubMed ID: 32417899 [No Abstract] [Full Text] [Related]
5. Favipiravir for COVID-19 in a Patient on Hemodialysis. Hirai D; Yamashita D; Seta K Am J Kidney Dis; 2021 Jan; 77(1):153-154. PubMed ID: 33011311 [No Abstract] [Full Text] [Related]
6. Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study. Dabbous HM; Abd-Elsalam S; El-Sayed MH; Sherief AF; Ebeid FFS; El Ghafar MSA; Soliman S; Elbahnasawy M; Badawi R; Tageldin MA Arch Virol; 2021 Mar; 166(3):949-954. PubMed ID: 33492523 [TBL] [Abstract][Full Text] [Related]
7. A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial. Bosaeed M; Mahmoud E; Hussein M; Alharbi A; Alsaedy A; Alothman A; Aljeraisy M; Alqahtani H; Nashabat M; Almutairi B; Almaghaslah M; Aldibasi O; AlJohani S; Bouchama A; Arabi Y; Alaskar A Trials; 2020 Oct; 21(1):904. PubMed ID: 33129363 [TBL] [Abstract][Full Text] [Related]
8. The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial. Li J; Zhang C; Wu Z; Wang G; Zhao H Trials; 2020 Jun; 21(1):488. PubMed ID: 32503657 [TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials. Hassanipour S; Arab-Zozani M; Amani B; Heidarzad F; Fathalipour M; Martinez-de-Hoyo R Sci Rep; 2021 May; 11(1):11022. PubMed ID: 34040117 [TBL] [Abstract][Full Text] [Related]
10. Understanding the pharmacokinetics of Favipiravir: Implications for treatment of influenza and COVID-19. Ison MG; Scheetz MH EBioMedicine; 2021 Jan; 63():103204. PubMed ID: 33418497 [No Abstract] [Full Text] [Related]
11. Favipiravir and COVID-19: A Simplified Summary. Ghasemnejad-Berenji M; Pashapour S Drug Res (Stuttg); 2021 Mar; 71(3):166-170. PubMed ID: 33176367 [TBL] [Abstract][Full Text] [Related]
12. Fingernail lunula luminescence in COVID-19 patients: Is it a favipiravir-related reaction or a novel manifestation of coronavirus infection. Kutlu Ö; Yılmaz Ş Photodermatol Photoimmunol Photomed; 2021 Jul; 37(4):343-344. PubMed ID: 33480085 [No Abstract] [Full Text] [Related]
13. Favipiravir use for SARS CoV-2 infection. Boretti A Pharmacol Rep; 2020 Dec; 72(6):1542-1552. PubMed ID: 33108587 [TBL] [Abstract][Full Text] [Related]
14. Systematic Review on Repurposing Use of Favipiravir Against SARS-CoV-2. Nasir M; Perveen RA; Saha SK; Talha KA; Selina F; Islam MA Mymensingh Med J; 2020 Jul; 29(3):747-754. PubMed ID: 32844821 [TBL] [Abstract][Full Text] [Related]
15. Re: Efficacy of favipiravir in adults with mild COVID-19 by Bosaeed et al. Mori N Clin Microbiol Infect; 2022 Oct; 28(10):1399. PubMed ID: 35562086 [No Abstract] [Full Text] [Related]
16. Japan's Drug Regulation During the COVID-19 Pandemic: Lessons From a Case Study of Favipiravir. Ueda M; Tanimoto T; Murayama A; Ozaki A; Kami M Clin Pharmacol Ther; 2022 Mar; 111(3):545-547. PubMed ID: 33882157 [No Abstract] [Full Text] [Related]
17. Tackling COVID-19 Using Remdesivir and Favipiravir as Therapeutic Options. Sreekanth Reddy O; Lai WF Chembiochem; 2021 Mar; 22(6):939-948. PubMed ID: 33031623 [TBL] [Abstract][Full Text] [Related]
18. An adaptive randomised placebo controlled phase II trial of antivirals for COVID-19 infection (VIRCO): A structured summary of a study protocol for a randomised controlled trial. McMahon JH; Lau JSY; Roney J; Rogers BA; Trubiano J; Sasadeusz J; Molton JS; Gardiner B; Lee SJ; Hoy JF; Cheng A; Peleg AY Trials; 2020 Oct; 21(1):847. PubMed ID: 33050947 [TBL] [Abstract][Full Text] [Related]
19. Combined treatment of molnupiravir and favipiravir against SARS-CoV-2 infection: One + zero equals two? Eloy P; Le Grand R; Malvy D; Guedj J EBioMedicine; 2021 Dec; 74():103663. PubMed ID: 34768087 [No Abstract] [Full Text] [Related]
20. A review on favipiravir: the properties, function, and usefulness to treat COVID-19. Hashemian SM; Farhadi T; Velayati AA Expert Rev Anti Infect Ther; 2021 Aug; 19(8):1029-1037. PubMed ID: 33372567 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]